Thermo Fisher Scientific (NYSE:TMO), the global leader in serving science, delivered a strong start to the 2026 fiscal year, reporting first-quarter results that surpassed analyst expectations for both top-line growth and profitability.
For the period ended March 28, 2026, the Waltham, Massachusetts-based company achieved revenue of $11.01 billion, representing a 6% increase compared to the first quarter of 2025.
The company’s bottom-line performance was equally robust, supported by disciplined operational execution through its proprietary PPI (Practical Process Improvement) Business System.
GAAP diluted earnings per share (EPS) grew 11% to $4.43, while adjusted EPS—which excludes certain non-recurring items—rose 6% to $5.44.
The margin expansion reflects a favorable product mix and continued demand for high-end analytical instrumentation and clinical research services.
Thermo Fisher’s performance was further bolstered by stable demand from its core pharmaceutical and biotech customer base, alongside a steady recovery in academic and government spending.
The company continues to benefit from its strategic focus on high-growth emerging markets and its comprehensive portfolio that spans laboratory equipment, life sciences solutions, and specialty diagnostics.